Extended‐release buprenorphine in pregnancy-Reference-Cited by-同舟云学术

Extended‐release buprenorphine in pregnancy

Published:2024-01-24 Issue:3 Volume:33 Page:354-356
ISSN:1055-0496
Container-title:The American Journal on Addictions
language:en
Short-container-title:American J Addict

Author:

Hubbell Alexander¹^ORCID,Aghenta Ese²,Jones Cresta³,Specker Sheila²

Affiliation:

1. M Health Fairview Addiction Medicine University of Minnesota Minneapolis Minnesota USA

2. Department of Psychiatry University of Minnesota Minneapolis Minnesota USA

3. Department of Obstetrics, Gynecology, and Women's Health University of Minnesota Minneapolis Minnesota USA

Abstract

AbstractBackground and ObjectivesThe relative safety and efficacy of monthly extended‐release buprenorphine (XR‐BUP) has not been fully evaluated in pregnant persons.MethodsCase report of two pregnant individuals receiving XR‐BUP while pregnant.ResultsBoth patients had positive experiences and healthy infants.Discussion and ConclusionsSparse data regarding the use of XR‐BUP in pregnant patients limits shared decision‐making. Additional evidence will support the growing population of pregnant patients exposed to XR‐BUP.Scientific SignificancePositive patient experiences using XR‐BUP during pregnancy have been previously unreported. This report will contribute to discussions of risks and benefits for future patients using XR‐BUP during pregnancy.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajad.13518

Reference14 articles.

1. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2. US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020

3. Maternal Opioid Drug Use during Pregnancy and Its Impact on Perinatal Morbidity, Mortality, and the Costs of Medical Care in the United States

4. American College of Obstetricians and Gynecologists. Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711.Obstet Gynecol.2017;130(2):e81‐e94.doi:10.1097/AOG.0000000000002235

5. US Food and Drug Administration Center for Drug Evaluation and Research.Department of health and human services. NDA approval: SUBLOCADE;2017. Accessed November 24 2022.https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209819Orig1s000ltr.pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Buprenorphine/buprenorphine/naloxone;Reactions Weekly;2024-02-17